First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy Volunteers.
Sungpil HanYo Han KimHee Youn ChoiDong-Jun SohJeongmin KimJoonwoo NamJong-Woo KimKyun-Seop BaeHyeong-Seok LimPublished in: Drug design, development and therapy (2020)
The tolerable dose ranges and pharmacokinetic characteristics of JPI-289 evaluated in these studies will be useful in further clinical development of JPI-289.